Edison Investment Research - Baywa AG (BYW) QuickView: Systematic internationalisation strategy

Report

Edison Investment Research

QuickView: Systematic internationalisation strategy

Since 2009, BayWaâ€™s management has strengthened the group by entering international markets, developing global procurement and distribution capabilities, and diversifying into the renewable energy market. This enables the group to benefit from growth in emerging markets and reduces the impact of weather-related variations in agricultural commodity prices. In parallel, management has exited from non-core or underperforming businesses, eg selling off certain building merchantsâ€™ sites in H114.

28/05/2015 2 EN

Underlying

Baywa AG

See profile

DE0005194005 Germany

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

ING Financial Markets

Commissioned Research: BayWa AG - Issuer profile

BayWa AG was founded in 1923 and is headquartered in Munich, Germany. The BayWa registered share is traded on the regulated market/Prime Standard regulated market on the Frankfurt am Main and Munich stock exchanges and in the XETRA trading system.

May 24, 2019 May 24, 2019 1 EN

Oddo BHF

BayWa AG : Q2 2018 results show expected catch-up effects; Q3 2018 set to benefit from rising agricultural commodity prices

>Q2 2018 results slightly ahead of our estimates - BayWa reported Q2 2018 group EBIT up 13% yoy to â‚¬ 73.1m, slightly ahead of our â‚¬ 70.0m estimate. As expected, the company benefited from weather-related catch-up effects in its segments Agri Supply & Trade (BAST), and Building Materials. H2 2018e should be propelled by the sale of Renewable Energy Projects and improving trading profits thanks to increasing agricultural commodity prices. We leave our full-year 2018 EBI...

August 13, 2018 August 13, 2018 5 EN

Oddo BHF

ODDO BHF GERMAN MORNING NEWS â€“ DETAILED COMMENTS 06.13.2018

...

June 13, 2018 June 13, 2018 8 EN

Actinogen Medical - First patient dosed in Phase IIb XanaMIA study

Actinogen Medical announced that the first randomised patient in its Phase IIb XanaMIA trial of lead candidate Xanamem received their first treatment on Friday 12 April. This study is designed to enrol c 220 patients with cognitive impairment (CI) associated with biomarker-positive mild-to-moderate Alzheimer’s disease (AD), as confirmed through an elevated level of phosphorylated Tau-181 (pTau-181) protein in their blood at baseline. The study has commenced at 13 Australian sites and will concentrate on domestic sites for the first c 100 patients, and initial efficacy and safety results will b...

3h / 23m 3h / 23m 1 EN

Sean Conroy

Sean Conroy

Cereno Scientific - CS014 (thrombosis) progresses towards the clinic

Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibitor with epigenetic effects, to the clinic with the submission of the clinical trial application (CTA) to the European Medicines Agency (EMA). The CTA is for the first-in-human Phase I trial for CS014, which Cereno is developing for thrombosis prevention, without increased risk of bleeding. We believe this has the potential to address the main limitation of current standard-of-care antithrombotic medicines and offers a sizeable opportunity for Cereno (backed by supportive preclinical data). Subje...

3h / 44m 3h / 44m 1 EN

Pedro Fonseca

Pedro Fonseca

Tetragon Financial Group - FY23 growth driven by idiosyncratic factors

Tetragon Financial Group (Tetragon) posted a 6.4% net asset value (NAV) per share total return (TR) in US dollar terms in FY23. Tetragon’s returns normally have a low correlation with broader markets, and therefore its FY23 performance was below the 26.3% return of the S&P 500 Index, which rallied on the artificial intelligence (AI) theme. Tetragon’s FY23 return on equity (RoE) of 5.5% was below its target of 10–15% pa. That said, its performance since listing was within the target range at 11.3%. Tetragon continues payouts to its shareholders, distributing US$83.6m in FY23 through buybacks an...

4h / 55m 4h / 55m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN